Year: 2019
Type: article
Study design: Observational Study
Abstract: Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau ( MAPT ) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.
Authors: Qin Chen, Bradley F. Boeve, Matthew Senjem, Nirubol Tosakulwong, Timothy G. Lesnick, Danielle Brushaber, Christina Dheel, Julie Fields, Leah Forsberg, Ralitza Gavrilova, Debra Gearhart, Jonathan Graff‐Radford, Neill R. Graff‐Radford, Clifford R. Jack, David T. Jones, David S. Knopman, Walter K. Kremers, Maria Lapid, Rosa Rademakers, Jeremy Syrjanen, Adam L. Boxer, Howie Rosen, Zbigniew K. Wszolek, Kejal Kantarci
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,000
Funders: U.S. Department of Defense, Mayo Clinic, Alzheimer's Association, Amgen, Alzheimer's Drug Discovery Foundation, Association for Frontotemporal Degeneration, Eli Lilly and Company, Pfizer, AstraZeneca, Novartis, Roche, Biogen, University of Southern California, AbbVie, Little Family Foundation, Ionis Pharmaceuticals, Sol Goldman Charitable Trust, TauRx Pharmaceuticals, National Institutes of Health, Genentech, GE Healthcare, Avid Radiopharmaceuticals, Tau Consortium, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: G1173778324, G2929235049, Pathological basis of MRS and DTI changes in neurodegenerative dementia, National Alzheimer's Coordinating Center, G6425121803, G650779111, Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS), The Frontotemporal Lobar Degeneration Clinical Research Consortium, Genetic Discovery and Pathobiology of Frontotemporal Lobar Degeneration and Related TDP-43 Proteinopathies, G8374629944, G8506111834, G9000030076, G9000302427, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
OpenAlex ID: W2964386366